Continue Terbinafine 250 mg Daily for Toenail Onychomycosis
Yes, continue terbinafine 250 mg once daily for the full 12-week course, as this patient is on the standard FDA-approved regimen with normal baseline liver function and no reported adverse effects. 1
Standard Treatment Duration
The FDA-approved regimen for toenail onychomycosis is terbinafine 250 mg once daily for 12 weeks, which this patient is currently completing. 1
British Association of Dermatologists guidelines recommend 12–16 weeks of continuous therapy, with the longer 16-week course reserved for more extensive disease. 2
Clinical trials demonstrate that 12 weeks of continuous terbinafine achieves mycological cure in 70–82% of patients with toenail infections, with complete cure rates of 38–69% at 48-week follow-up. 1, 3, 4
Why This Patient Should Continue
Normal baseline comprehensive metabolic panel indicates no contraindication to continuing therapy, as terbinafine is contraindicated only in patients with active or chronic liver disease. 2, 1
The optimal clinical effect occurs months after treatment completion due to the time required for healthy nail outgrowth, so stopping prematurely would compromise efficacy. 1
Continuous daily dosing is significantly more effective than pulse regimens, with one 2023 study showing 76.67% clinical cure with continuous therapy versus only 26.67% with pulse dosing. 5
Monitoring During Therapy
Periodic liver enzyme monitoring is recommended during treatment, especially if hepatic symptoms develop (persistent nausea, anorexia, fatigue, right upper abdominal pain, jaundice, dark urine, or pale stools). 2, 1
In a 2023 retrospective cohort of 735 patients, 5.2% had elevated AST and 8.4% had elevated ALT after one month of terbinafine, but none required discontinuation for hepatotoxicity. 6
Patients should be counseled to immediately report taste disturbance, smell disturbance, or depressive symptoms, as these warrant discontinuation. 2, 1
Important Safety Counseling
Warn about potentially permanent taste disturbance (dysgeusia), which can be severe and is the most concerning non-hepatic adverse effect. 2, 1
Advise minimizing sun exposure, as photosensitivity reactions have been reported with terbinafine. 1
Instruct to report any signs of severe skin reactions (hives, mouth sores, blistering, facial swelling, difficulty swallowing or breathing), which require immediate discontinuation and emergency care. 1
Post-Treatment Expectations
Clinical reassessment should occur 3–6 months after starting therapy to evaluate response and detect adverse effects. 2
The mean time to overall success is approximately 10 months for toenail infections, reflecting the slow nail growth rate. 1
Recurrence occurs in approximately 15–25% of treated patients, so counsel on preventive measures including antifungal powders in footwear and avoiding barefoot walking in public areas. 2, 1
Common Pitfalls to Avoid
Do not stop therapy early even if the nail appears improved, as mycological cure requires the full treatment duration and clinical improvement lags behind fungal eradication. 1
Do not switch to pulse dosing to reduce cost or improve adherence, as continuous therapy is significantly more effective. 5, 7
Do not neglect to obtain baseline liver function tests before initiating therapy, though this patient already has normal values documented. 2, 1